Novel spiroketal pyrrolidine GSK2336805 potently inhibits key hepatitis C virus genotype 1b mutants: From lead to clinical compound

Journal of Medicinal Chemistry

Volumn 57, Issue 5, 2014, Pages 2058-2073

  Kazmierski, Wieslaw M ^a   Maynard, Andrew ^a   Duan, Maosheng ^b   Baskaran, Sam ^a   Botyanszki, Janos ^a   Crosby, Renae ^a   Dickerson, Scott ^a   Tallant, Matthew ^a   Grimes, Rick ^a   Hamatake, Robert ^a   Leivers, Martin ^a   Roberts, Christopher D ^a   Walker, Jill ^a  

^a GLAXOSMITHKLINE   (United States)

^b HD Biosciences (China) Co Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIOXA 7AZASPIRO[4.4]NONANE; GSK 2336805; NONANE; NONSTRUCTURAL PROTEIN 5A INHIBITOR; PYRROLIDINE DERIVATIVE; UNCLASSIFIED DRUG; VIRUS RNA;

ARTICLE; CONTROLLED STUDY; DRUG SAFETY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 1B; HUMAN; MUTANT; PROTEIN MOTIF; REPLICON; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DRUG DESIGN; GENOTYPE; HEPACIVIRUS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MODELS, MOLECULAR; MUTATION; PYRROLIDINES; RNA, VIRAL; SPIRO COMPOUNDS;

EID: 84896279723     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm4013104     Document Type: Article

References (36)

1. Alter, M. J. Epidemiology of hepatitis C virus infection World J. Gastroenterol. 2007, 13, 2436-2441
2. Kamal, S. M.; Fouly, A. E.; Kamel, R. R.; Hockenjos, B.; Al Tawil, A.; Khalifa, K. E.; He, Q.; Koziel, M. J.; El Naggar, K. M.; Rasenack, J.; Afdhal, N. H. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response Gastroenterology 2006, 130, 632-638
3. Tong, M. J.; El-Farra, N. S.; Reikes, A. R.; Co, R. L. Clinical outcomes after transfusion-associated hepatitis C N. Engl. J. Med. 1995, 332, 1463-1466
4. Adeel, A. B.; Fasiha, K. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients Clin. Infect. Dis. 2012, 54, 96-104
5. Lemon, S. M.; McKeating, J. A.; Pietschmann, T.; Frick, D. N.; Glenn, J. S.; Tellinghuisen, T. L.; Symons, J.; Furman, P. A. Development of novel therapies for hepatitis C Antiviral Res. 2010, 86, 79-92
6. Poenisch, M.; Bartenschlager, R. New insights into structure and replication of the hepatitis C virus and clinical implications Semin. Liver Dis. 2010, 30, 333-347
7. Gao, M.; Nettles, R. E.; Belema, M.; Snyder, L. B.; Nguyen, V. N.; Fridell, R. A.; Serrano-Wu, M. H.; Langley, D. R.; Sun, J.-H.; O'Boyle, D. R., II; Lemm, J. A.; Wang, C.; Knipe, J. O.; Chien, C.; Colonno, R. J.; Grasela, D. M.; Meanwell, N. A.; Hamann, L. G. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect Nature 2010, 465, 96-100
8. Fridell, R. A.; Qiu, D.; Wang, C.; Valera, L.; Gao, M. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system Antimicrob. Agents Chemother. 2010, 54, 3641-3650
9. Lemm, J. A.; Leet, J. E.; O'Boyle, D. R.; Romine, J. L.; Huang, X. S.; Schroeder, D. R.; Alberts, J.; Cantone, J. L.; Sun, J. H; Nower, P. T.; Martin, S. W.; Serrano-Wu, M. H.; Meanwell, N. A.; Snyder, L. B.; Gao, M. Discovery of potent hepatitis C virus NS5A inhibitors with dimeric structures Antimicrob. Agents Chemother. 2011, 55, 3795-3802
10. Romine, J. L.; St. Laurent, D. R.; Leet, J. E.; Martin, S. W.; Serrano-Wu, M. H.; Yang, F.; Gao, M.; O'Boyle, D. R.; Lemm, J. A.; Sun, J.-H.; Nower, P. T.; Huang, X.; Deshpande, M. S.; Meanwell, N. A.; Snyder, L. B. Inhibitors of HCV NS5A: from iminothiazolidinones to symmetrical stilbenes ACS Med. Chem. Lett. 2011, 2, 224-229
11. Lopez, O. D.; Nguyen, V. N.; St. Laurent, D. R.; Belema, M.; Serrano-Wu, M. H.; Goodrich, J. T.; Yang, F.; Qiu, Y.; Ripka, A. S.; Nower, P. T.; Valera, L.; Liu, M.; O'Boyle, D. R.; Sun, J. H.; Fridell, R. A.; Lemm, J. A.; Gao, M.; Good, A. C.; Meanwell, N. A.; Snyder, L. B. HCV NS5A replication complex inhibitors. Part 3: Discovery of potent analogs with distinct core topologies Bioorg. Med. Chem. Lett. 2013, 23, 779-784
12. St Laurent, D. R; Belema, M.; Gao, M.; Goodrich, J.; Kakarla, R.; Knipe, J. O; Lemm, J. A; Liu, M.; Lopez, O. D; Nguyen, V. N; Nower, P. T.; O'Boyle, D.; Qiu, Y.; Romine, J. L.; Serrano-Wu, M. H.; Sun, J. H.; Valera, L.; Yang, F.; Yang, X.; Meanwell, N. A.; Snyder, L. B. HCV NS5A replication complex inhibitors. Part 2: Investigation of stilbene prolinamides Bioorg. Med. Chem. Lett. 2012, 22, 6063-6
13. Schmitz, U.; Tan, S.-L. NS5A-from obscurity to new target for HCV therapy. Recent patents on anti-infective Drug Discovery 2008, 3, 77-92
14. Cordek, D. G.; Bechtel, J. T.; Maynard, A. T.; Kazmierski, W. M.; Cameron, C. E. Targeting the protein NS5A protein of HCV: an emerging option Drugs Future 2011, 36, 691-711
15. Hamatake, R.; Maynard, A.; Kazmierski, W. M. HCV Inhibition mediated through the nonstructural protein 5A (NS5A) replication complex Annu. Rep. Med. Chem. 2012, 47, 331-345
16. Schmitz, F. U.; Roberts, C. D.; Abadi, A. D. M.; Griffith, R. C.; Leivers, M. R.; Slobodov, I.; Rai, R. N-Heterocyclylpyrrolidine carboxamide derivatives, processes for preparing them, pharmaceutical compositions containing them, and their use as antiviral agents. WO 2007/070600, 2006.
17. Maynard, A.; Crosby, R. M.; Ellis, B.; Hamatake, R.; Hong, Z.; Johns, B. A.; Kahler, K. M.; Koble, C.; Leivers, A.; Leivers, M. R.; Mathis, A.; Peat, A. J.; Pouliot, J. J.; Roberts, C. D.; Samano, V.; Schmidt, R. M.; Smith, G. K.; Spaltenstein, A.; Stewart, E. L.; Thommes, P.; Turner, E. M.; Voitenleitner, C.; Walker, J. T.; Waitt, G.; Weatherhead, J.; Weaver, K.; Williams, S.; Wright, L.; Xiong, Z. Z.; Haigh, D.; Shotwell, J. B. Discovery of a potent boronic acid derived inhibitor of the HCV RNA-dependent RNA polymerase. J. Med. Chem. 2013, DOI: 10.1021/jm400317w.
18. Leivers, M. R.; Schmitz, F. U.; Griffith, R. C.; Roberts, C. D.; Dehghani Mohammad Abadi, A.; Chan, S. A.; Rai, R.; Slobodov, I.; Ton, T. L. Preparation of thiazolidine derivatives as antiviral agents. WO 2008/064218, 2007.
19. Schmitz, F. U.; Rai, R.; Roberts, C. D.; Kazmierski, W.; Grimes, R. Preparation of biphenyls and biheteroaryls end-capped with amino acid or peptide derivatives as antivirals for treating Flaviviridae family virus infection. WO 2010/062821, 2009.
20. Guedj, J.; Dahari, H.; Rong, L.; Sansone, N. D.; Nettles, R. E.; Cotler, S. J.; Layden, T J.; Uprichard, S. L.; Perelson, A. S. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 3991-3996
21. Lemm, J. A.; O'Boyle, D.; Liu, M.; Nower, P.; Colono, R.; Deshpande, M.; Snyder, L.; Martin, S.; St. Laurent, D.; Serrano-Wu, M.; Romine, J.; Meanwell, N.; Gao, M. Identification of hepatitis C virus NS5A inhibitors J. Virol. 2010, 84, 482-491
22. Targett-Adams, P.; Graham, E. J. S.; Middleton, J.; Palmer, A.; Shaw, S.; Lavender, H.; Brain, P.; Tran, T. D.; Jones, L.; Wakenhut, F.; Stammen, B.; Pryde, D.; Pickford, C.; Westby, M. Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action J. Virol. 2011, 85, 6353-6358
23. O'Boyle, D. R.; Sun, J. H.; Nower, P. T.; Lemm, J. A.; Fridell, R. A.; Wang, C.; Romine, J. L.; Belema, M.; Nguyen, V. N.; Laurent, D. R.; Serrano-Wu, M.; Synder, L. B.; Meanwell, N.; Langley, D.; Gao, M. Characterizations of HCV NS5A replication complex inhibitors Virology 2013, 444, 343-354
24. Tellinghuisen, T. L.; Marcotrigiano, J.; Rice, C. M. Structure of the zinc-finding comain of an essential replicase component of hepatisis C virus reveals a novel fold Nature 2005, 435, 374-379
25. Love, R. A.; Brodsky, O.; Hickey, M. J.; Wells, P. A.; Cronin, C. N. Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus J. Virol. 2009, 83, 4395-4403
26. Penin, F.; Brass, V.; Appel, N.; Ramboarina, S.; Montserret, R.; Ficheux, D.; Blum, H. E.; Bartenschlager, R.; Moradpour, D. Structure and function of the membrane anchor domain of hepatitis C virus nonstructural protein 5A J. Biol. Chem. 2004, 279, 40835-40843
27. Fridell, R. A.; Qiu, D.; Valera, L.; Wang, C.; Rose, R. E.; Gao, M. Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A Inhibitor BMS-790052 J. Virol. 2011, 85, 7312-7320
28. Chen, P.; Couch, R.; Duan, M.; Grimes, R. M.; Kazmierski, W. M.; Norton, B. A.; Tallant, M. Preparation of biphenyls end capped with amino acids or peptide derivatives for treating HCV infection. WO 2011/028596, 2010.
29. Baskaran, S.; Botyanszki, J.; Cooper, J. P.; Duan, M.; Kazmierski, W. M.; Mcfadyen, R. B.; Redman, A. Preparation of phenylene, pyridinylene, furanylene and thiofuranylene linked benzimidazoles and derivatives end capped with peptide derivatives for treating HCV infection. WO 2011/050146, 2010.
30. Baskaran, S.; Dickerson, S. H.; Duan, M.; Kazmierski, W. M.; McFadyen, R. B. Preparation of naphthalenylene, quinolinylene and isoquinolinylene linked benzimidazole-imidazoles and analogs end capped with peptide derivatives for treating HCV infection. WO 2011/091446, 2011.
31. Wang, C.; Huang, H.; Valera, L.; Sun, J.-H.; O'Boyle, D. R., II; Nower, P. T; Jia, L.; Qiu, D.; Huang, X.; Altaf, A.; Gao, M.; Fridella, R. A. Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052 Antimicrob. Agents Chemother. 2012, 56, 1350-1358
32. Siebum, A. H. G.; Woo, W. S.; Raap, J.; Lugtenburg, J. Access to any site-directed isotopomer of methionine, selenomethionine, cysteine, and selenocysteine-use of simple, efficient modular synthetic reaction schemes for isotope incorporation Eur. J. Org. Chem. 2004, 13, 2905-2913
33. Henriksen, B. S.; Anderson, J. L.; Hrycyna, C. A.; Gibbs, R. A. Synthesis of desthio prenylcysteine analogs: sulfur is important for biological activity Bioorg. Med. Chem. Lett. 2005, 15, 5080-5083
34. Sóti, F.; Kajtár-Peredy, M.; Keresztury, G.; Incze, M.; Kardos-Balogh, Z.; Szántay, C. Synthesis of vinca alkaloids and related compounds. LV. Synthesis of (±)-desmethoxy cuanzine Tetrahedron 1991, 47, 271-296
35. Walker, J.; Crosby, R.; Wang, A.; Woldu, E.; Vamathevan, J.; You, S.; Voitenleitner, C.; Remlinger, K.; Duan, M.; Kazmierski, W.; Hamatake, R. Preclinical characterization of GSK2336805, a novel inhibitor of hepatitis C virus replication that selects for resistance in NS5A Antimicrob. Agents Chemother. 2014, 58, 38-47
36. Spreen, W.; Wilfret, D.; Bechtel, J.; Adkison, K. K.; Lou, Y.; Jones, L.; Willsie, S. K.; Glass, S. J.; Roberts, C. D. GSK2336805 HCV NS5A inhibitor demonstrates potent antiviral activity in chronic genotype 1 infections: results from a first time in human (FTIH) single and repeat dose study. Presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco, CA, U.S., Nov 6-9, 2011; Hepatology, 2011, 54, 400A.